Meeting
2019 ASCO Annual Meeting
A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Authors
Jill J.J. Geenen
Netherlands Cancer Institute, Amsterdam, Netherlands
Jill J.J. Geenen , Gwen Dackus , Philip C. Schouten , Dick Pluim , Serena Marchetti , Gabe S. Sonke , Alwin Huitema , Jos H. Beijnen , Jan H. M. Schellens , Sabine C. Linn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Pharmacology/Pharmacodynamics/Pharmacogenetics
Clinical Trial Registration Number
NCT02418624
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3118)
DOI
10.1200/JCO.2019.37.15_suppl.3118
Abstract #
3118
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: U.S. retrospective cohort study.
First Author: Ramez Nassef Eskander
Poster
2022 ASCO Annual Meeting
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
First Author: Florian Heitz
Poster
2020 ASCO Virtual Scientific Program
A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.
First Author: Filip Janku
Poster
2013 ASCO Annual Meeting
Phase I dose escalation study of the protein kinase C iota inhibitor aurothiomalate for advanced non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
First Author: Aaron Scott Mansfield